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Cathepsin S (CTSS), a lysosomal cysteine protease with elastase activity across 42 
a wide pH range is elevated in COPD clinical samples, but it’s role in the disease 43 
process is unknown. This study demonstrates that CTSS significantly contributes 44 
to cigarette smoke-induced loss of lung function in mice. CTSS expression is 45 
negatively regulated by protein phosphatase 2A (PP2A) but PP2A activity is 46 
inhibited by prolonged exposure to cigarette smoke. Chemical activation of PP2A 47 
reduces induction of CTSS expression in the lung and loss of lung function. Thus, 48 
these findings demonstrate a major role of CTSS and PP2A in smoke-induced 49 
COPD and identify a new potential therapeutic target to treat COPD. Finally, our 50 
results and approaches suggest that pharmacological activation of important 51 
upstream signaling enzymes, such as phosphatases (PP2A), that negatively 52 
regulate key effectors associated with COPD progression, such as CTSS may 53 
represent an alternative and possibly complementary approach to direct effector 54 
enzyme inhibition. 55 
This article has an online data supplement, which is accessible from this issue's 56 
table of content online at www.atsjournals.org 57 
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Abstract 58 
Rationale: Cathepsin S (CTSS) is a cysteine protease that is observed at higher 59 
concentrations in bronchoalveolar lavage fluid and plasma of chronic obstructive 60 
pulmonary disease (COPD) subjects.  61 
Objectives: The objective of this study was to investigate whether CTSS is 62 
involved in the pathogenesis of cigarette smoke-induced COPD and determine 63 
whether targeting upstream signaling could prevent the disease.  64 
Methods: CTSS expression was investigated in animal and human tissue and cell 65 
models of COPD. Ctss-/- mice were exposed to long-term cigarette smoke and 66 
forced oscillation and expiratory measurements were recorded. Animals were 67 
administered chemical modulators of protein phosphatase 2A (PP2A) activity. 68 
Measurements and Main Results: Here we observed enhanced CTSS 69 
expression and activity in mouse lungs following exposure to cigarette smoke. 70 
Ctss-/- mice were resistant to cigarette smoke-induced inflammation, airway 71 
hyperresponsiveness, airspace enlargements and loss of lung function. CTSS 72 
expression was negatively regulated by PP2A in human bronchial epithelial cells 73 
isolated from healthy non-smokers and COPD donors and in monocyte-derived 74 
macrophages. Modulating PP2A expression or activity, with silencer short 75 
interfering RNA or a chemical inhibitor or activator, during acute smoke exposure 76 
in mice altered inflammatory responses and CTSS expression and activity in the 77 
lung. Enhancement of PP2A activity prevented chronic smoke-induced COPD in 78 
mice. 79 
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Conclusions: Our study indicates that the decrease in PP2A activity that occurs 80 
in COPD contributes to elevated CTSS expression in the lungs and results in 81 
impaired lung function. Enhancing PP2A activity represents a feasible therapeutic 82 
approach to reduce CTSS activity and counter smoke-induced lung disease. 83 
 84 
Key words: Cigarette smoke, cathepsin S, phosphatase and chronic obstructive 85 
pulmonary disease 86 
 87 
 88 
Introduction 89 
Lifelong cigarette smoke exposure decreases pulmonary function in susceptible 90 
smokers leading to the onset and progression of chronic obstructive pulmonary 91 
disease (COPD) (1). COPD is currently the third leading cause of death in the US 92 
(2) and is a major global health problem. Exposure to cigarette smoke is the 93 
primary environmental factor associated with COPD formation in the developed 94 
world. Cellular responses triggered by cigarette smoke cause the release of 95 
inflammatory and proteolytic mediators that contribute to the pathogenesis of 96 
COPD (3). Though the role of proteases in COPD is well established, much of the 97 
research has focused on serine elastase and matrix metalloproteinases (MMP) (4, 98 
5). In particular, the role of the cathepsin (CTS) family of enzymes, which are highly 99 
expressed in COPD, remains to be determined.  100 
Several CTS are induced by smoke inhalation and are linked to emphysema 101 
development, including CTS E (6), G (7), K (8) and S (9). CTSS is a lysosomal 102 
cysteine protease that exerts elastase activity across a wide range of pH in alveolar 103 
 3 
 
macrophages, fibroblasts and epithelial cells. CTSS activity is significantly 104 
elevated in the BALF (10) and plasma of COPD patients (11). Altered CTSS levels 105 
are associated with a variety of pathological conditions including cystic fibrosis 106 
(CF), arthritis, cancer, and cardiovascular disease (12). CTSS has multiple 107 
functional roles, including major histocompatibility complex class II antigen 108 
presentation (13) and it can also cleave and inactivate key innate immunity 109 
proteins, such as β-defensins 2 and 3 (14), secretory leukocyte protease inhibitor 110 
(15) and lactoferrin (16). Unlike other CTS, CTSS has activity at a neutral pH (17) 111 
and increased levels of CTSS would have proteolytic activity in a healthy lung. 112 
Therefore, determining the stimuli that increase CTSS activity may provide key 113 
insights into the pathogenesis of lung diseases.  114 
In view of the potential link between CTSS and COPD progression, we 115 
explored whether cigarette smoke alters CTSS signaling and determined whether 116 
CTSS impairs lung function and structure. Here we demonstrate that smoke 117 
exposure triggers robust Ctss expression and enhanced proteolytic activity in the 118 
lungs of mice. Using Ctss-/- mice, we determined that Ctss expression directly 119 
impacts cigarette smoke-induced changes in pulmonary physiology. One plausible 120 
mechanism for smoke induction of CTSS expression is inactivation of protein 121 
phosphatase 2A (PP2A), a phosphatase that regulates inflammatory and 122 
proteolytic responses (18-20). Chronic smoke exposure diminishes lung PP2A 123 
responses and coincides with airspace enlargement in response to smoke (19, 124 
21). Inhibition of PP2A in mice prior to smoke exposure, enhanced CTSS 125 
expression and lung inflammation. Equally, normalizing PP2A levels in mice or in 126 
human bronchial epithelial (HBE) cells isolated from COPD subjects reduced 127 
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CTSS expression and secretion. Chemical activation of PP2A prevents cigarette 128 
smoke induced loss of lung function in mice and this study presents data showing, 129 
PP2A regulation of CTSS that alters lung immune and proteolytic responses to 130 
responsible for airway injury and function.  131 
 132 
 133 
Methods 134 
Detailed and expanded methodology is included in the Online Supplement. 135 
Animal models  136 
Ctss-/- mice, on a C57BL/6J background, were exposed to cigarette smoke in a 137 
chamber (Teague Enterprises) for four hours daily, five days per week at a total 138 
particulate matter concentration of 80-120 mg/m3 with the University of Kentucky 139 
reference research cigarettes 3R4F (Lexington). An additional group of wild-type 140 
mice were intraperitoneally (IP) injected with 2 μg/kg of okadaic acid (LC Labs) or 141 
intranasal delivery of 7.4 nmol PP2AA (mouse Ppp2r1a) silencer short, interfering 142 
RNA (Life Technologies). PP2A activity was enhanced in mice by oral 143 
administration of 50 mg/kg of a bioavailable small molecule activator of PP2A 144 
(SMAP; see (22)) twice daily. All animal experiments were performed with approval 145 
from SUNY Downstate’s Institutional Animal Care and Use Committee and in strict 146 
accordance with the recommendations in the Guide for the Care and Use of 147 
Laboratory Animals of the National Institutes of Health and Institutional Animal 148 
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Care and Use Committee (IACUC) guidelines and according to the Declaration of 149 
Helsinki conventions for the use and care of animals. 150 
Forced oscillation and expiratory measurements 151 
Mice were anesthetized, tracheostomized and connected via an endotracheal 152 
cannula to the SCIREQ flexiVent system (SCIREQ Inc.). Animals were paralyzed 153 
and pulmonary function measured (23). Airway responses to increasing doses of 154 
methacholine were assessed.  155 
Histology and lung immune cell measurements 156 
Bronchoalveolar lavage fluid (BALF) and BALF cells were obtained from animals 157 
of each group and assessed by flow cytometry (24). Lungs underwent pressure-158 
fixation and morphometric analysis in accordance with the ATS/ERS issue 159 
statement (25). Mean linear intercept analysis was performed (26). Alveolar 160 
counts, boundary size and ductal destructive measurements were performed (27). 161 
Sections from human bronchial tissue (28) and mouse lung tissue were stained for 162 
CTSS.  163 
Cell culture 164 
HBE cells from non-smokers and COPD patients were isolated from human organ 165 
donor lungs rejected for transplant and fully re-differentiated at the ALI as 166 
previously described (29). Consent for research was obtained by the Life Alliance 167 
Organ Recovery Agency of the University of Miami. All consents were IRB-168 
approved and conformed to the Declaration of Helsinki. Cells were transfected with 169 
purified PP2A protein (Millipore) using Pro-Ject transfection reagent (Pierce) as 170 
per the manufacturers' instructions (18). Cells were also transfected with PP2A or 171 
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HuR specific siRNA. Alternatively, cell media were supplemented with 1 μM SMAP. 172 
Monocyte-derived macrophages were also examined for PP2A regulation of 173 
CTSS. 174 
PP2A and CTSS measurements 175 
Immunoblots for ERK phosphorylation (Thr202/Tyr204 and total ERK), the A 176 
subunit of PP2A and β-Actin (Cell Signaling Technologies) were performed. PP2A 177 
activity was determined using the Millipore PP2A activity assay (17-313, Millipore). 178 
Gene expression was performed by qPCR using Taqman probes (Applied 179 
Biosystems). CTSS concentrations were determined in BALF using a CTSS ELISA 180 
kit (R&D Systems) and immunoblots. CTSS activity was determined, as previously 181 
described (30).  182 
Statistical analyses 183 
Data are expressed as mean ± S.E.M. Data were compared by Student’s t test 184 
(two-tailed) or by two-way ANOVA and Tukey’s post hoc test analysis, using 185 
GraphPad Prism Software (Version 6.0h for Mac OS X). 186 
 187 
 188 
Results  189 
Cigarette smoke enhances CTS expressions and CTSS activity in mouse 190 
lungs.  191 
To investigate the impact of cigarette smoke on CTS expressions, C57BL/6J 192 
animals were exposed to cigarette smoke daily for several time points. Lung CTS 193 
expressions were determined by qPCR and CTSS was further analyzed by ELISA, 194 
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substrate activity assays and immunoblots. First, the gene expression of all CTS 195 
family members was examined in the lungs of mice exposed to smoke for 6-196 
months, with gene expression relative to each other CTS gene. Ctse, Ctsg and 197 
Ctss were significantly altered by smoke exposure in the lungs (Figure 1A and 198 
Figure E1). We primarily focused on CTSS as higher levels are observed in the 199 
BALF (10) and plasma of COPD patients (11). Smoke exposure resulted in a 200 
significant increase in CTSS levels and activity in BALF (Figure 1B). Lung tissue 201 
analysis also confirmed that there is elevated CTSS activity within the tissue of 202 
smoke exposed animals (Figure 1B). Western blot analysis confirmed elevated 203 
CTSS proteins levels in BALF from mice exposed to cigarette smoke, as early as 204 
8 days post exposure and remained high throughout exposure (Figure 1B). 205 
Immunofluorescence evaluation demonstrated that CTSS is elevated in smoke- 206 
exposed mice and CTSS is located in immune and epithelial cells (Figure 1C). 207 
Therefore smoke exposure elevates several CTS genes in the lungs. 208 
Ctss deficiency prevents smoke-induced loss of lung function in mice.  209 
To determine whether Ctss expression impacted on airway resistance and lung 210 
function in mice, Ctss-/- mice and their wild-type littermates were exposed to 211 
cigarette smoke daily for 6 months. Airway resistance was assessed by 212 
methacholine challenge test. At every methacholine dose ≥4 mg/mL, Ctss-/- mice 213 
exposed to cigarette smoke showed significantly lower respiratory resistance than 214 
wild-type mice exposed to cigarette smoke (Figure 2A). To examine how Ctss 215 
deficiency altered lung function in response to cigarette smoke, pressure volume 216 
(PV) loops, compliance and FEV0.05/FVC were determined as previously described 217 
(23). A PV loop that shifts up and to the left, suggests an emphysematous lung as 218 
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observed in wild-type mice exposed to smoke (Figure 2B). However, the PV loop 219 
from Ctss-/- mice exposed to smoke did not shift up. Lung compliance is a measure 220 
of the lung's ability to stretch and expand, and FEV0.05/FVC is the proportion of the 221 
animal’s vital capacity that is expired in the first one-twentieth of a second of forced 222 
expiration to the full vital capacity. In mice, smoke inhalation typically enhances 223 
compliance and reduces FEV0.05/FVC levels (Figure 2C). Importantly, Ctss-/- mice 224 
developed less emphysematous changes following exposure to smoke compare 225 
to controls, with reduced smoke-induced changes in lung function in all three 226 
parameters observed in these mice.  227 
Immune cell infiltration is frequently observed in the lungs of COPD patients 228 
(31). Total BALF immune cell counts were significantly increased in smoke-229 
exposed wild-type mice, but not in Ctss-/- mice (Figure 3A). Lung macrophages 230 
and neutrophils were reduced in Ctss-/- mice following smoke exposure compared 231 
to wild-type mice (Figure 3A). However, Ctss expression did not impact eosinophil, 232 
T or B cell numbers in the lungs (Figure 3A). Smoke exposure did enhance T and 233 
B cell frequency in the airways, in a CTSS-independent manner (Figure 3A). 234 
Morphometric quantification demonstrated that the loss of Ctss expression 235 
prevented the increase in smoke-induced airspace enlargements, determined by 236 
mean linear intercept (MLI) analysis (Figure 3B). Since CTSS is a potent elastase, 237 
elastin degradation was investigated by quantifying plasma levels of desmosine, 238 
an amino acid found in elastin. Smoke- exposed Ctss-/- mice had reduced 239 
desmosine in their plasma compared to wild type mice (Figure 3C), indicating less 240 
elastin degradation. Parenchymal airspace profiling (27) was utilized to 241 
demonstrate that Ctss-/- mice had a higher alveolar count, reduced loss of alveolar 242 
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boundary and reduced ductal destruction compared to smoke-exposed wild-type 243 
mice (Figure 3D). Therefore, Ctss expression impacts on lung function, 244 
inflammation, elastin degradation and lung tissue remodeling during chronic 245 
cigarette smoke exposure. 246 
 247 
HBE cells isolated from COPD patients express more CTSS than cells from 248 
non-smokers without COPD partially due to altered PP2A signaling.  249 
Previous work has identified airway epithelial cells as a source of pulmonary CTSS 250 
(32). Here, we further investigated CTSS levels in human bronchial tissue to 251 
confirm the presence of CTSS and elevated levels in COPD samples. 252 
Immunofluorescence analysis demonstrated that CTSS is expressed by bronchial 253 
tissue and is elevated in bronchial tissue from COPD subjects (Figure 4A). To 254 
explore further the regulation of CTSS expression, we utilized HBE cells isolated 255 
from non-smokers, and COPD subjects. Cells isolated from COPD subjects 256 
expressed and secreted more CTSS than cells from non-smokers (Figure 4B-E). 257 
The stabilizing RNA-binding protein human antigen R (HuR) and the phosphatase, 258 
PP2A, have been linked to the regulation of CTSS expression in atherosclerosis 259 
(33) and Alzheimer's disease/Down syndrome (34). Therefore, we examined 260 
CTSS gene expression and activity in HBE cells following modulation of HuR or 261 
PP2A signaling. Loss of HuR expression, with siRNA transfection, did not 262 
significantly alter CTSS signaling in HBE cells from non-smokers or COPD 263 
subjects (Figure 4B). However, transfecting siRNA specific for the A subunit of 264 
PP2A (PP2AA) (Figure 4C) or PP2A protein into HBE cells (Figure 4D) or the 265 
treatment of HBE cells with a small molecular activator of PP2A (SMAP) (Figure 266 
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4E) significantly altered CTSS expression and activity in both cell groups. 267 
Modulated PP2A signaling was confirmed by the regulation of ERK 268 
phosphorylation in these cells, with reduced ERK phosphorylation observed when 269 
PP2A is active (Figure 4D-E).  270 
Other cell types also express CTSS, such as macrophages (10). Human 271 
monocytes were isolated from peripheral blood of non-smokers and derived into 272 
macrophages. Similar to HBE cells, silencing PP2AA enhanced CTSS expression 273 
and activity in monocyte-derived macrophages (Figure 4F). Alternatively, SMAP 274 
treatment enhanced PP2A activity and reduced ERK and CTSS responses (Figure 275 
4G). Therefore, loss of PP2A activity appears to result in enhanced CTSS 276 
expression and enzyme activity, possibly contributing to disease development. 277 
 278 
Triggering PP2A responses prevents smoke-induced CTSS expression in 279 
mice. 280 
To examine PP2A modulation and acute smoke effects on Ctss expression, wild-281 
type mice were exposed to cigarette smoke daily for 3 days while they were 282 
administered daily injections of the phosphatase inhibitor okadaic acid,   intranasal 283 
delivery of PP2AA silencer short interfering RNA or twice daily oral administration 284 
of SMAP (18, 19, 22). Mice treated with okadaic acid had significantly higher 285 
infiltrating immune cells into the lung after smoke exposure compared to controls 286 
(Figure 5A). Okadaic acid treatment also enhanced lung ERK phosphorylation. In 287 
response to cigarette smoke, lung Ctss gene expression and BALF CTSS activity 288 
were significantly increased in okadaic acid-treated mice. Similarly, silencing 289 
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PP2AA in the lungs enhanced inflammation, ERK phosphorylation and CTSS 290 
responses in mice (Figure 5B). Alternatively, administration of SMAP to mice 291 
reduced smoke-induced immune cell infiltration, ERK phosphorylation, as well as 292 
CTSS expression and enzyme activity (Figure 5C).  293 
To determine the long-term effects of SMAP treatment on lung function, 294 
wild-type mice were administered SMAP twice daily during 2-month exposures to 295 
cigarette smoke. A/J mice were chosen as they are more sensitive to cigarette 296 
smoke induced emphysema-like symptoms than other mouse backgrounds (35). 297 
Animal weight was recorded throughout the study and liver to body weight ratio 298 
was measured at the end, as indicators of chemically induced changes to organs. 299 
No significant changes in weight were observed between groups (Figure 6A). 300 
Treatment with SMAP reduced smoke-induced immune cell infiltration into the 301 
airways (Figure 6B) and prevented smoke-induced inhibition of PP2A activity 302 
within the lungs (Figure 6C) which coincided with reduced lung Ctss gene and 303 
protein release into the airways during smoke exposure (Figure 6D). As expected, 304 
SMAP treatment was not able to completely block smoke- induced CTSS 305 
responses (Figure 6D) . Nevertheless, it showed the importance of PP2A in 306 
regulating CTSS.  307 
To examine whether SMAP treatment prevents the alteration of lung 308 
function in response to cigarette smoke, we examined PV loops, compliance and 309 
FEV0.05/FVC. The PV loop analysis from SMAP treated mice were lower compared 310 
to vehicle treated animals, when exposed to smoke (Figure 7A). SMAP treated 311 
mice developed less emphysematous changes following exposure to smoke 312 
compared to controls, with reduced smoke-induced changes in lung function in 313 
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compliance and FEV0.05/FVC (Figure 7B). SMAP administration reduced 314 
desmosine levels in their plasma compared to vehicle treated animals (Figure 7C). 315 
SMAP-treated animals had higher alveolar counts and reduced ductal destruction 316 
compared to smoke exposed vehicle treated mice (Figure 7D). SMAP 317 
administration also prevented the increase in smoke-induced airspace 318 
enlargements, determined by MLI analysis (Figure 7E). These SMAP-mediated 319 
changes in CTSS levels were observed without changes in inflammation, such as 320 
IL1β (36), IFNγ (32) and TNFα (Figure E2A-B). Equally, SMAP administration did 321 
not impact smoke- induced Ctse or Ctsg (Figure E2C). Therefore, SMAP treatment 322 
impacts on lung function, inflammation, elastin degradation and lung tissue 323 
remodeling during chronic cigarette smoke exposure. 324 
 325 
 326 
Discussion 327 
Here, we establish that cigarette smoke enhances CTSS levels and activity, at 328 
least partly, due to a reduction in PP2A activity. Furthermore, CTSS contributes to 329 
cigarette smoke-induced COPD (Figure 7F). Ctss-/- mice were resistant to cigarette 330 
smoke-induced loss of lung function. Elevated levels of CTSS are observed in the 331 
lungs of mice from 8 days after the initiation of smoke inhalation and persisted 332 
throughout exposure. Expression of CTSS in the airway epithelium appears to be 333 
regulated by PP2A and not HuR. However, it is possible that HuR stabilizes CTSS 334 
mRNA in other cell types, as previously reported (33). Therefore, we propose that 335 
CTSS promotes the loss of lung function in COPD and also modulates pulmonary 336 
inflammatory responses. Either directly targeting CTSS activity or enhancing PP2A 337 
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activity to decrease CTSS expression may represent a plausible means to counter 338 
COPD progression. Importantly, pharmacological reactivation of the endogenous 339 
enzyme, PP2A, negatively regulates CTSS expression and prevented smoke-340 
induced loss of lung function. 341 
Neutrophil elastase and MMPs are the most frequent proteases implicated 342 
in the pathogenesis of COPD. Single-nucleotide polymorphisms (SNPs) in MMP1, 343 
MMP9 (37) and MMP12 (38) are associated with COPD. However, of the 344 
numerous protease inhibitory molecules tested, only one elastase inhibitor, 345 
Sivelestat (ONO-5046), is currently approved for the treatment of acute lung injury 346 
but not COPD due to toxicity issues (39). In recent years, CTSS has received more 347 
attention as a target for multiple diseases (12) and our data here outlines the 348 
potential importance of inhibiting CTSS to reduce progression of COPD. Since 349 
CTSS activity is elevated in COPD patient samples (10, 11) and CTSS is activated 350 
at a neutral pH (17), increased levels of CTSS would have proteolytic activity in a 351 
healthy lung and may be a critical step in establishing early stage COPD. We and 352 
others have demonstrated that CTSE and CTSG are also enhanced by smoke 353 
exposure (6, 9). Both CTSE (6) and CTSG (7) play important roles in disease 354 
progression but appear not to be regulated at the transcriptional level by SMAP 355 
treatment. Our results establish the role of CTSS in early disease development 356 
and suggest that targeting this protease could be an effective therapeutic strategy 357 
in COPD.  358 
We explored several mechanisms to determine how smoke exposure 359 
enhanced CTSS expression in the lungs. Inflammatory mediators can influence 360 
CTSS expression, with IFNγ (32), TNFα and IL1β (36) all linked to CTSS 361 
 14 
 
expression. However, we did not observe significant changes in these 362 
inflammatory mediators following SMAP administration but cannot rule out these 363 
or other unidentified factors regulating CTSS levels in COPD. We also explored 364 
HuR and PP2A as potential regulators of CTSS. Editing of RNA integrity is 365 
associated with the progression of multiple diseases, including cardiovascular 366 
disease (33). Recruitment of the stabilizing RNA-binding protein human antigen R, 367 
HuR, to the 3' UTR of the CTSS transcript, enhances CTSS mRNA stability and 368 
expression (33). HuR expression did not impact CTSS expression in HBE cells in 369 
this study. However, we cannot completely rule out the possibility of HuR or other 370 
RNA stabilizing proteins playing a role on Ctss expression in smoke exposed 371 
lungs. Cigarette smoke extract alters HuR expression to modulate SNAIL signaling 372 
in small airway epithelial cells (40). It is conceivable that HuR could exert similar 373 
effects to stabilize and enhance CTSS expression in the COPD lung. Investigating 374 
how the mRNA stability of key COPD associated genes alters the initiation and 375 
progression of this disease is an important future area of study. In our findings, 376 
however, PP2A appears to be the primary factor responsible for changes in CTSS 377 
expression. We previously observed increased Ctss expression and reduced 378 
PP2A activity in mice exposed to smoke while infected with respiratory syncytial 379 
virus (RSV) (9). In this current study, we directly show that the loss of PP2A 380 
signaling is responsible for elevated CTSS expression in mice and HBE cells. This 381 
is important, as inhibition of PP2A coincides with multiple changes in the lungs, 382 
including immune responses (19), mucus production (41), protease expression 383 
(18) and corticosteroid sensitivity (42). The SMAP compound utilized in this study 384 
inhibit tumor formation via activation of PP2A (22, 43). The SMAP compound 385 
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activates PP2A by binding to the A subunit of PP2A, promoting conformational 386 
changes, which increase cellular phosphatase activity (22) and promoting PP2A 387 
holoenzyme (ABC subunit) assembly and perturbs interactions with endogenous 388 
PP2A inhibitors. Other compounds, such as erlotinib, FTY-720, and analogous 389 
synthetic sphingolipids, also activate PP2A (44-46) by binding the endogenous 390 
PP2A inhibitors, cancerous inhibitor of PP2A (CIP2A) or inhibitor 2 of PP2A 391 
(I2PP2A/SET), and de-repressing PP2A activity. These could also be possible 392 
therapeutic candidates for the treatment of COPD. Our data with smoke exposure 393 
in combination with small molecule activators of PP2A suggests that this class of 394 
compounds could be considered for the treatment of smoke-associated diseases 395 
and warrant further preclinical investigations. 396 
In addition, direct CTSS enzyme inhibitors are currently being investigated 397 
in multiple disease models. For example, RO5459072, a CTSS inhibitor, 398 
suppresses systemic and peripheral disease-associated mechanisms of 399 
autoimmune tissue injury in mice (47). RO5459072 also reduced CD4 T cell and 400 
dendritic cell activation, and autoantibody production in a preclinical model of 401 
spontaneous systemic lupus erythematosus and lupus nephritis (48). CTSS 402 
inhibition also reduces the inflammatory responses of macrophages by causing 403 
these cells to secrete less proinflammatory cytokines and express less MHC class 404 
II and CD80 (49). Thus, the therapeutic benefits of reducing CTSS activity may be 405 
achieved in two ways: upstream by exploiting the negative regulation of CTSS 406 
transcription via PP2A activation, as shown in the present study, and directly by 407 
inhibiting CTSS enzyme activity directly. Combination therapy potential of SMAPs 408 
and CTSS inhibitors may be beneficial in several ways, i.e. allow reduced dosing 409 
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of CTSS inhibitors to minimize its potential toxicity and targeting the neutrophil pool 410 
of CTSS (47). Advancing our current studies, we will focus on combinational 411 
therapy potential, including the use of CTSS inhibitors and other therapeutic 412 
agents.  413 
Together, our data identify PP2A’s negative regulation of CTSS as an 414 
important factor in smoke-induced COPD, as reduction in CTSS expression 415 
prevents loss of lung function, reduces inflammation, slows the degradation of 416 
elastin and lung tissue remodeling. Indeed, our work highlights that targeting the 417 
PP2A/CTSS pathway may limit smoke-induced COPD. 418 
 419 
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 608 
Figure Legends 609 
Figure 1. Smoke exposure enhances Ctss gene and protein expression in 610 
mice lungs.  611 
(A) CTS genes were quantified in C57BL/6J lung tissue, following 6 months 612 
exposure to room air and cigarette smoke, by qPCR and are shown as relative 613 
gene expression to each CTS gene. (B) CTSS protein and activity were quantified 614 
in the BALF of C57BL/6J mice following 6 months exposure to room air and 615 
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cigarette smoke by ELISA and substrate activity assays, respectively. CTSS 616 
activity was also determined in total lung tissue protein. Immunoblots were also 617 
performed on BALF from C57BL/6J mice exposed to cigarette smoke for 0, 8 days, 618 
2 months or 6 months. The CTSS pro form is 37 kDa and the active form is 25 619 
kDa. Every lane represents an individual mouse. (C) Immunofluorescence was 620 
performed on lung tissue from room air and smoke- exposed mice for CTSS and 621 
DAPI. Comparative images of the two mouse groups are presented here (scale 622 
bars = 150 µm). CTSS fluorescence intensity was determined and arbitrary units 623 
(A.U.) are shown here. Data are represented as mean ± S.E.M, with each 624 
measurement performed on 3 separate days from at least 4 animals/group. * 625 
denotes p value <0.05, when comparing both treatments connected by a line, 626 
determined by student t-tests. 627 
 628 
Figure 2. Ctss deficiency prevents smoke-induced loss of lung function in 629 
mice.  630 
Wild-type and Ctss-/- mice were exposed to room air and cigarette smoke for 6 631 
months. (A) Animals were challenged for airway resistance by a dose response of 632 
methacholine. (B-C) Negative pressure-driven forced expiratory and forced 633 
oscillation technique maneuvers were performed in all animal groups. (B) Pressure 634 
volume loops, (C) compliance and forced expiration (FEV) in the first 0.05 second 635 
of forced vital capacity (FVC) was determined in each animal. Data are 636 
represented as mean ± S.E.M, where n=10 per group. * denotes a p value <0.05, 637 
when comparing both treatments connected by a line, determined by 2-way 638 
ANOVA with Tukey's post hoc test. 639 
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 640 
Figure 3. Ctss deficiency prevents smoke-induced lung immune cell 641 
infiltration and airspace enlargements in mice.  642 
Wild-type and Ctss-/- mice were exposed to room air and cigarette smoke for 6 643 
months. (A) BALF total immune cells, neutrophils, alveolar macrophages, 644 
eosinophils, T cells and B cells were quantified in each group by flow cytometry. 645 
(B) Mean linear intercepts (MLI) were measured in the lungs of the mice to assess 646 
air space size and comparative histology images of the four mouse groups are 647 
presented here (scale bars=40 µm). (C) Plasma desmosine levels were 648 
determined in smoke exposed animals by ELISA. (D) Alveolar count, alveolar 649 
boundary and ductal/destructive fractions were quantified in each animal by 650 
parenchymal airspace profiling. Data are represented as mean ± S.E.M, where 651 
n≥5 per group. * denotes a p value <0.05, when comparing both treatments 652 
connected by a line, determined by 2-way ANOVA with Tukey's post hoc test or 653 
Student T-Test when comparing only 2 groups. 654 
 655 
Figure 4. HBE cells from COPD patients have enhanced CTSS responses due 656 
to PP2A inhibition.  657 
(A) Bronchial tissue from non-smokers and COPD subjects were stained for CTSS 658 
(red), DAPI (blue) and acetylated tubulin (green) and CTSS staining intensity was 659 
quantified. Images are x20 magnification. HBE cells isolated from non-smokers 660 
without COPD and COPD individuals were transfected with (B) scrambled or HuR 661 
siRNA, (C) scrambled or PP2AA siRNA and (D) albumin or active PP2A protein or 662 
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(E) treated with SMAP. Gene expression of CTSS was determined in all cells and 663 
CTSS activity quantified in media. Immunoblots were performed to confirm 664 
transfection efficiency for (A) HuR and β-Actin and (B-C) ERK phosphorylation as 665 
a downstream readout of PP2A activity. (F/G) Peripheral blood monocytes from 666 
non-smokers were derived into macrophages and transfected with (F) scrambled 667 
or PP2AA siRNA or (G) treated with SMAP. CTSS gene expression, PP2A and 668 
CTSS activities and immunoblots were determined. Data are represented as mean 669 
± S.E.M., where each measurement was performed on 3 independent days and 670 
with n≥3 subjects per group. * denotes a p value <0.05, when comparing both 671 
treatments connected by a line, determined by 2-way ANOVA with Tukey's post 672 
hoc test. 673 
 674 
Figure 5. Modulating PP2A signaling alters acute smoke-induced lung Ctss 675 
expression. Mice were exposed to room air and cigarette smoke and either (A) 676 
daily injections of okadaic acid (2 μg/kg IP), (B) intranasally administered 677 
scrambled or PP2AA silencer short interfering RNA, or (C) two oral administrations 678 
of SMAP daily for 3 days. Mice were euthanized 24 hours post last exposure (n = 679 
5 for each group). BALF cellularity levels were examined in each mouse. 680 
Immunoblots were performed for ERK phosphorylation as a downstream readout 681 
of PP2A and total levels of PP2AA and β-Actin were included as controls. Lung 682 
Ctss gene expression and BALF CTSS activity were examined by qPCR and 683 
substrate activity assays, respectively. * denotes a p value <0.05, when comparing 684 
both treatments connected by a line, determined by 2-way ANOVA with Tukey's 685 
post hoc test. 686 
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 687 
Figure 6. Activating PP2A signaling alters long-term smoke-induced lung 688 
Ctss expression. A/J mice were exposed to room air and cigarette smoke and 689 
two oral administration of SMAP daily for 2 months. Mice were euthanized 24 hours 690 
post last exposure (n = 9 for each group). (A) Liver to body weight ratios and whole-691 
body weights were recorded in each group. (B) BALF cellularity levels were 692 
examined in each mouse. (C) Lung PP2A activity, (D) lung Ctss gene expression 693 
and BALF CTSS activity were examined by substrate activity assays, qPCR and 694 
substrate activity assays, respectively. * denotes a p value <0.05, when comparing 695 
both treatments connected by a line, determined by 2-way ANOVA with Tukey's 696 
post hoc test. 697 
 698 
Figure 7. Activating PP2A signaling prevents smoke-induced loss of lung 699 
function. Mice were exposed to room air and cigarette smoke and two oral 700 
administrations of SMAP daily for 2 months. (A/B) Negative pressure-driven forced 701 
expiratory and forced oscillation technique maneuvers were performed in all 702 
animal groups. (A) Pressure volume loops, (B) compliance and forced expiration 703 
extension (FEV) in the first 0.05 second of forced vital capacity (FVC) were 704 
determined in each animal. (C) Plasma desmosine levels were assessed in 705 
smoke-exposed animals by ELISA. (D) Alveolar count and ductal/destructive 706 
fractions were quantified in each animal by parenchymal airspace profiling. (E) 707 
Mean linear intercepts (MLI) were measured in the lungs of the mice to assess air 708 
space size and comparative histology images of the four mouse groups are 709 
presented here (scale bars=40 µm). Data are represented as mean ± S.E.M, 710 
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where n=9 per group. * denotes a p value <0.05, when comparing both treatments 711 
connected by a line, determined by 2-way ANOVA with Tukey's post hoc test. (F) 712 
Possible signaling mechanism for PP2A regulation of CTSS. Evidence presented 713 
in this study indicates that PP2A prevents signaling leading to CTSS gene 714 
expression but following smoke exposure CTSS expression is enhanced and the 715 
phosphatase activity of PP2A is diminished. This enhancement of CTSS directly 716 
impacts lung function. 717 
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